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Sleeve gastrectomyAbstract Background and objectives: Sleeve gastrectomy has become a popular and effective treat-
ment for morbidly obese patients. The aim of this prospective randomized study was to assess the
efficacy of multimodal analgesia using pregabalin and dexmedetomidine in morbidly obese patients
undergoing laparoscopic sleeve gastrectomy.
Materials and methods: After ethical approval 60 American Society of Anesthesiologists (ASA)
physical status II patients were enrolled in this study and allocated randomly into 2 groups: group
A received 75 mg oral pregabalin 2 h before surgery and dexmedetomidine infusion 0.4 lg/kg/h and
group B (control group) received placebo capsule 2 h before surgery and saline infusion intraoper-
atively. Intraoperative fentanyl consumption, hemodynamics and postoperative opioid consump-
tion, pain scores, level of sedation and any side effects were evaluated.
Results: There was a significant decrease in heart rate, mean arterial blood pressure, pain score,
intraoperative fentanyl use, postoperative morphine consumption and nausea verbal rating scale
in group A compared to group B. There was a significant increase in sedation score in group A com-
pared to group B.
Conclusions: The combination of preoperative oral pregabalin and intraoperative dexmedeto-
midine infusion decreased intraoperative fentanyl use and ensured postoperative better pain control
and less postoperative opioid consumption.
 2016 Publishing services by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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This is the first study to investigate the effect of combination of
oral pregabalin and dexmedetomidine infusion in morbidly
obese patients undergoing sleeve gastrectomy. Multimodal
analgesia is a technique which is achieved by combining differ-
ent types of analgesics that act by different mechanisms of
action and at different sites in the nervous system, resulting in
additive or synergistic analgesia with lower incidence of adverse
effects than the administration of individual analgesics [1].
As the incidence of obesity is being increased, bariatric pro-
cedures are increasingly being performed all over the world.
Bariatric surgery is an effective treatment for obesity, with a
mean percentage of weight loss after 2 years of 68.2% for
laparoscopic sleeve gastrectomy [2]. Morbidly obese patients
may be sensitive to the respiratory depressant effect of opioid
analgesics and more likely to require postoperative ventilation
to avoid postoperative hypoxia [3].
Dexmedetomidine is a highly selective a2 adrenergic recep-
tor agonist; it has anxiolytic, sedative, analgesic and sympa-
tholytic properties without significant respiratory depressant
effects [4,5]. The combination of sedative and analgesic effects
with minimal respiratory depression of dexmedetomidine is of
great value in the morbidly obese patient who may be at risk of
postoperative obstructive apnea, respiratory depression and
opioid-induced respiratory depression following laparoscopic
bariatric surgery [6,7].
Pregabalin is a structural analogue of the inhibitory neuro-
transmitter c-aminobutyric acid [8]. It binds to the a-2-d sub-
unit of voltage-gated excitatory calcium channels, reducing
the release of many excitatory neurotransmitters and prevent-
ing the development of hyperalgesia and sensitization of dorsal
horn neurons [9,10]. Pregabalin has anticonvulsant, anti-
hyperalgesic, and anxiolytic properties similar to gabapentin,
but it has a more favorable pharmacokinetic profile, including
high oral bioavailability [11,12]. It is also more potent than
gabapentin with fewer side effects [8]. Recently, pregabalin
has been used in multimodal analgesia for acute postoperative
pain [13]. The gap in literature is the absence of a definite one
technique to provide proper pain control in this risky group of
patients without significant side effects and opioid sparing
properties.
The aim of this study is to evaluate the effects of combining
dexmedetomidine infusion and oral pregabalin on supplemen-
tal opioid requirements, pain scores and hemodynamic param-
eters during the first 24 h; in morbidly obese patients
undergoing laparoscopic sleeve gastrectomy. This prospective
randomized double blind placebo controlled study assigned
patients to receive pregabalin plus dexmedetomidine or pla-
cebo, we expected that this combination of drugs administered
would demonstrate additive and prolonged postoperative anal-
gesia. The primary outcome was total amount of postoperative
morphine consumption; secondary outcome measures were
pain and sedation scores, intraoperative fentanyl consumption,
postoperative nausea and vomiting, hemodynamic variables
and time to ambulation.2. Patients and methods
After obtaining informed written consents, and obtaining
approval from Research Ethics Committee of anesthesiologydepartment, this prospective randomized double blind con-
trolled parallel-group with allocation ratio of (1:1) was con-
ducted in Cairo university hospitals. A total of 60 morbidly
obese patients with American Society of Anesthesiologists
(ASA) physical status classification II, aged 18–50 years, of
both sex, undergoing elective laparoscopic sleeve gastrectomy
were enrolled in this study. Exclusion criteria included myocar-
dial dysfunction (ejection fraction <40%), renal or hepatic
dysfunction, inability to use the visual analogue scale (VAS),
allergy to any of the study drugs, current treatment with
narcotics, antihypertensives, benzodiazepines, a2 agonists,
antiepileptics and antipsychotics.
Two hours before induction of anesthesia, patients were
randomly allocated using computer generated randomization
numbers, and sealed in closed opaque envelopes, into one of
2 groups: group A (n= 30) received 75 mg oral pregabalin
(Lyrica, Pfizer) and group B (n= 30) received placebo
capsule.
On arrival to the preparation room intravenous cannula was
inserted under local anesthesia, no sedation was given. In the
operating theater standard monitors, non-invasive blood pres-
sure, oxygen saturation and electrocardiogram were applied
before induction of anesthesia, capnography after induction
of anesthesia and baseline heart rate (HR), mean arterial blood
pressure (MAP) and oxygen saturation (SpO2) were recorded.
Then the patients of group A started dexmedetomidine
(Precedex 100 lg/ml, Hospira) infusion 0.4 lg/kg/h after a
bolus of 0.5 lg/kg intravenously over 10 min and patients of
group B received a bolus of saline then saline infusion identical
to group A. Patients and investigators recording data in the
operating room were blinded to the treatment given.
All patients in both groups received standardized anesthetic
technique in the form of intravenous (i.v.) propofol 2 mg/kg, i.v.
fentanyl 1–2 lg/kg and atracurium 0.5 mg/kg to facilitate endo-
tracheal intubation, mechanical ventilation was adjusted to
keep end tidal carbon dioxide (EtCO2) between 30 and
35 mmHg, and all drugs were based on ideal body weight.
Sevoflurane 2% in 50% oxygen and air, and 0.15 mg/kg atra-
curium every 20 min were given for maintenance of anesthesia.
Intraoperative hemodynamic variables and supplemental fen-
tanyl requirements were recorded. Intraoperative HR, MAP,
EtCO2 and SpO2 values were recorded at 5 min intervals till
the end of operation. HR and MAP were maintained within
±20% of the baseline values. Hypotension (defined as
MAP< 20% of the baseline value) treated by a bolus of
200 ml Ringer’s solution if not responding increments of
3–9 mg ephedrine was given. Hypertension (defined as
MAP> 20%of the baseline value) and/or tachycardia (defined
as HR> 20% of the baseline value) a supplemental dose (25–
50 lg) fentanyl was given or increasing concentration of
sevoflurane. Bradycardia (HR < 50 beat per minute) persisting
for>2 minwas treated with atropine, 0.4 mg i.v. boluses. Intra-
operatively i.v. ondansetron, 4 mg (Zofran, GlaxoSmithKline)
was given for prevention of postoperative nausea and vomiting.
Before skin closure, all ports of laparoscope were infiltrated
with 0.25% bupivacaine. By the end of surgery sevoflurane
was discontinued and the residual neuromuscular block was
antagonized with neostigmine 0.05 lg/kg, given with atropine
0.02 mg/kg, the endotracheal tube was removed after return
of spontaneous breathing, and the patient was obeying com-
mands in semi-sitting position, then the patient was transferred
to the post-anesthesia care unit (PACU), where the patients
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system that was programmed to deliver morphine, 1 mg i.v.
boluses on demand with a lockout interval of 20 min. MAP,
SpO2 and HR were documented preoperatively as baseline,
every 5 min; intraoperatively and in PACU then hourly in the
first postoperative day (POD). Pain was evaluated using Visual
Analogue Scale (VAS) for pain (0 = no pain to 10 = the worst
pain); every 2 h in the first POD, if VAS > 4, supplemental dose
of 2 mg morphine was given. Total amount of narcotics was
recorded. Nausea levels were assessed using 11-point verbal rat-
ing scale (VRS) (0 = no nausea and 10 = the worst nausea
ever). Nausea VRS was obtained every 30 min till discharge
from PACU then every 2 h in the first POD. A protocol for
antiemetic drugs was administrated according to nausea VRS
scores: when the VRS score is 0–2 the patients received no antie-
metic drugs, when the VRS score is 3–6 the patients received one
dose of antiemetic drugs and when the VRS score is 7–10 the
patients received two or more doses of antiemetic drugs to a tar-
get VRS of 0–2 [14]. Rescue medications were the following in
order of administration: metoclopramide 10 mg, ondansetron
4 mg and dexamethasone 8 mg.
Level of sedation was assessed every 2 h in the PACU using
Ramsay sedation score (RSS) [15]: 1 – Anxious, agitated or
restless; 2 – Cooperative and oriented; 3 – Responsive to com-
mands; 4 – Asleep, but response to light glabellar tap or loud
auditory; 5 – Asleep, sluggish response to glabellar tab or audi-
tory response; and 6 – Asleep, no response. Any episode of
vomiting, visual disturbance and other side effects was
documented. An independent, trained nurse blinded to the
study drugs being received assessed pain, level of sedation,
hemodynamic variables and nausea and/or vomiting.Assessed for eligibility (n=6
Randomized (n =60)
Group A (n=30), Allocated to 
intervention (n=30), Received 
pregabalin and DEX (n=30)
Lost to follow up (n = 0) 
Discontinued intervention (n = 0)
Analyzed (n = 30)
Excluded from analysis (n = 0) 
Allocaon 
Follow up
Analysis 
Figure 1 Flow diagraSample size was based on previous study [16] and calculated
by assuming that there was >50% reduction of the postoper-
ative morphine consumption by combination of both
dexmedetomidine and pregabalin and a error = 0.05 with
power of 80% resulted in 30 patients in each arm.
Statistical analysis: Data were coded and entered using the
statistical package SPSS (Statistical Package for the Social
Science) version 22. Data were summarized using mean and
standard deviation in quantitative data and using frequency
(count) and relative frequency (percentage) for categorical
data. Comparisons between groups were done by using
unpaired t test. For comparing categorical data, Chi square
(v2) test was performed. Exact test was used instead when
the expected frequency is less than 5. P-values less than 0.05
were considered as statistically significant.3. Results
From August 2015 to January 2016, 67 consecutive mor-
bidly obese patients undergoing laparoscopic sleeve gastrec-
tomy were considered for study inclusion. Seven patients
were excluded due to opioid, antihypertensive and antide-
pressant therapy and sixty patients were randomized for
the study (Fig. 1). There were no differences in patient char-
acteristics and operative time (Table 1). Also there was no
significant difference between the groups regarding postoper-
ative oxygen saturation. There was a statistically significant
decrease in the mean heart rate and mean arterial blood
pressure in group A compared to group B as shown in
Figs. 2 and 3.7)
Excluded (n=7): history of 
opioid, antidepressant and 
antihypertensive therapy
Group B (n=30), Received 
placebo (control group)
Lost to follow up (n = 0) 
Discontinued intervention (n = 0)
Analyzed (n = 30)
Excluded from analysis (n = 0) 
 
m of participants.
Table 1 Patients’ characteristics and duration of surgery.
Parameters Group A
(n= 30)
Group B
(n= 30)
P
value
Age (years) 33.80 ± 8.84 33.93 ± 9.14 0.954
BMI (kg/m2) 49.33 ± 3.30 48.77 ± 3.41 0.516
Gender M/F 13/17 11/19 0.598
Duration of surgery
(minutes)
117.77 ± 5.98 117.87 ± 6.54 0.951
Data are expressed as mean ± standard deviation or count; BMI:
body mass index, M: male, F: female.
Figure 2 Trends of heart rate, data are presented as mean and
standard deviation, * statistically significant lower HR in group A
compared to group B (p< 0.05), HR: heart rate.
Figure 3 Trends of mean arterial blood pressure, data are
presented as mean and standard deviation, * statistically signif-
icant lower MAP in group A compared to group B (p< 0.05),
MAP: mean arterial pressure.
Figure 4 Ramsay sedation score, data are presented as mean and
standard deviation, * statistically significant higher sedation scores
in group A compared to group B (p< 0.05).
Figure 5 Visual analogue scale, data are presented as mean and
standard deviation, * statistically significant lower VAS in group
A compared to group B (p< 0.05), VAS: Visual analogue scale.
Figure 6 Nausea verbal rating scale, data are presented as mean
and standard deviation, * statistically significant lower nausea
verbal rating scale in group A compared to group B (p< 0.05),
VRS: verbal rating scale.
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pared to group B during the first six hours and at 24th hours
postoperatively as shown in Fig. 4; this may be due to the
extended effect of pregabalin.
As regards VAS score, there was significant decrease in
group A as compared to group B in the first postoperative
day (p< 0.001) (Fig. 5).
As regards nausea, group B showed significantly higher
incidence of nausea than group A starting from the second
hour to the 18th hour postoperatively (Fig. 6). Ten patientsin group B experienced an attack of vomiting compared to
one patient in group A (p< 0.001).
There was significant increase in fentanyl consumption
intraoperatively and morphine postoperatively in group B
compared to group A (p< 0.001) as shown in Table 2.
Table 2 Narcotic consumption.
Parameters Group A
(n= 30)
Group B
(n= 30)
P value
Intraoperative
fentanyl
consumption (lg)
134.17 ± 36.84 254.17 ± 42.59 <0.001*
Postoperative
morphine
consumption (mg)
15.07 ± 2.65 45.93 ± 4.56 <0.001*
Data are presented as mean and standard deviation.
* Statistically significant lower narcotic consumption in group A
compared to group B (p< 0.05).
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The main finding of this study was significant reduction of
intraoperative and postoperative narcotic consumption in
patients received combination of dexmedetomidine and prega-
balin, and also these patients showed better control of intraop-
erative and postoperative mean blood pressure and heart rate.
In the postoperative period, pregabalin and dexmedetomidine
decreased pain scores and PCA morphine use and showed bet-
ter recovery profile compared with placebo.
The use of opioid drugs intraoperatively and postopera-
tively for pain management may increase the incidence of post-
operative respiratory depression and hypoxia in morbidly
obese patients undergoing laparoscopic sleeve gastrectomy
[17]. Therefore, the combination of two drugs with narcotic
sparing effects could be very beneficial in morbidly obese
patients with risk of obstructive sleep apnea.
Dexmedetomidine is a highly specific a2 agonist with seda-
tive and analgesic effects, its use has been approved for seda-
tion in intensive care unit [18], but its use intraoperatively to
decrease anesthetic and narcotic requirements is not fully
established.
In a study done by Aho et al. [19] in patients undergoing
laparoscopic tubal ligation, dexmedetomidine had reduced
pain scores and narcotic consumption and this is consistent
with the results of the current study.
In a similar trial, Arian et al. [4] reported that there was
66% reduction of postoperative morphine consumption when
dexmedetomidine was used.
Feld et al. [7] conducted a study in patients undergoing
open gastric bypass and concluded that when dexmedeto-
midine used to substitute for fentanyl attenuates blood pres-
sure and provides postoperative analgesia, and this is in line
with the current study as regards narcotic consumption.
Tufanogullari et al. [20] studied the effects of dexmedeto-
midine infusion during bariatric surgeries and concluded that
adjunctive use of an intraoperative dexmedetomidine infusion
reduced fentanyl use, antiemetic therapy, and the length of
stay in the PACU, and they recommended using dexmedeto-
midine infusion to minimize the intraoperative cardiovascular
adverse effects.
Pregabalin is a structural analogue of gamma-aminobutyric
acid, and it is an attractive adjunct for perioperative analgesia
as it can be taken on an empty stomach, does not lead to gas-
trointestinal upset, and is well tolerated [21].
Agarwal et al. [22] concluded that oral pregabalin 150 mg
given before surgery was effective in reducing postoperativepain and the postoperative patient-controlled fentanyl analge-
sia in patients undergoing laparoscopic cholecystectomy.
The results of the current study are in line with the findings
of Girija et al. [23] who reported that the administration of
oral pregabalin 150 or 300 mg as a single preoperative dose
was effective in reduction of postoperative pain and total
fentanyl requirements in patients undergoing lumbar disk
surgeries.
In a meta-analysis done by Zhang et al. [24], they
concluded that the perioperative use of oral pregabalin has
a significant opioid-sparing effect in the first 24 h after
surgery with reduced incidence of postoperative nausea and
vomiting, but visual disturbances were more common with
pregabalin administration.
Limitations to the present study were the administration of
a single dose of pregabalin, so its duration of action was time
limited. Two different analgesic drugs were used simultane-
ously, and it was much better to use a single drug to show
its precise effects. Also, sevoflurane consumption intraopera-
tively or length of hospital stay was not estimated. Other
limitation was the patient satisfaction and antiemetic therapies
were not documented. Further studies are recommended to
compare different doses of pregabalin combined with
dexmedetomidine.
5. Conclusions
The combination of preoperative oral pregabalin and intra-
operative dexmedetomidine infusion decreased intraoperative
fentanyl use and ensured postoperative better pain control
and less postoperative opioid consumption.
Conflict of interest
None.
References
[1] Chou R, Gordon DB, de Leon-Casasola OA, et al. Management
of postoperative pain: a clinical practice guideline from the
American Pain Society, the American Society of Regional
Anesthesia and Pain Medicine, and the American Society of
Anesthesiologists’ Committee on Regional Anesthesia,
Executive Committee, and Administrative Council. J Pain
2016;17(2):131–57.
[2] Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery. A
systematic review and meta-analysis. JAMA 2004;292:1724–37.
[3] Rawal N, Sjostrand U, Christofferson E, Dahlstrom B, Arvill A,
Rydman H. Comparison of intramuscular and epidural
morphine for postoperative analgesia in the grossly obese.
Influence of postoperative ambulation and pulmonary function.
Anesth Analg 1984;63:583–92.
[4] Arain SR, Ruehlow RM, Uhrich TD, Ebert TJ. The efficacy of
dexmedetomidine versus morphine for postoperative analgesia
after major inpatient surgery. Anesth Analg 2004;98:153–8.
[5] Ihmsen H, Saari TI. Dexmedetomidine. Pharmacokinetics and
pharmacodynamics. Anaesthesist 2012;61(12):1059–66.
[6] Hofer RE, Sprung J, Sarr MG, Wedel DJ. Anesthesia for a
patient with morbid obesity using dexmedetomidine without
narcotics. Can J Anaesth 2005;52:176–80.
[7] Feld JM, Hoffman WE, Stechert MM, Hoffman IW, Ananda
RC. Fentanyl or dexmedetomidine combined with desflurane for
bariatric surgery. J Clin Anesth 2006;18:24–8.
298 A.K. Salama, N.M. Abdallah[8] Manjushree N, Chakraborty A, Shashidhar K, Narayanaswamy
S. A review of the drug pregabalin. Int J Basic Clin Pharmacol
2015;4(4):601–5.
[9] Shneker BF, McAuley JW. Pregabalin: a new neuromodulator
with broad therapeutic indications. Ann Pharmacother
2005;39:2029–37.
[10] Chizh BA, Gohring M, Troster A, Quartey GK, Schmelz M,
Koppert W. Effects of oral pregabalin and aprepitant on pain
and central sensitization in the electrical hyperalgesia model in
human volunteers. Br J Anaesth 2007;98:246–54.
[11] Guay DR. Pregabalin in neuropathic pain: a more
‘pharmaceutically elegant’ gabapentin? Am J Geriatr
Pharmacother 2005;3:274–87.
[12] McKeage K, Keam SJ. Pregabalin: in the treatment of
postherpetic neuralgia. Drugs Aging 2009;26(10):883–92.
[13] Gilron I. Gabapentin and pregabalin for chronic neuropathic
and early postsurgical pain: current evidence and future
directions. Curr Opin Anaesthesiol 2007;20:456–72.
[14] Dabu-Bondoc S, Vadivelu N, Shimono C, English A,
Kosarussavadi B, Dai F, Shelley K, Feinleib J. Intravenous
dextrose administration reduces postoperative antiemetic rescue
treatment requirements and postanesthesia care unit length of
stay. Anesth Analg 2013;117(3):591–6.
[15] Ramsay MAE, Savege TM, Simpson BRJ, Goodwin R.
Controlled sedation with alpaxalone–alphadolone. BMJ
1974;2:656–9.
[16] Gurbet A, Basagan-Mogol E, Turker G, Ugun F, Kaya FN,
Ozcan B. Intraoperative infusion of dexmedetomidine reducesperioperative analgesic requirements. Can J Anaesth
2006;53:646–52.
[17] Holmes J, Maye JP. Postoperative respiratory depression and
unresponsiveness following epidural opiate administration: a
case report. AANA J 2004;72:126–8.
[18] Kamibayashi T, Maze M. Clinical use of alpha 2-adrenergic
agonists. Anesthesiology 2000;93:1345–9.
[19] Aho MS, Erkola OA, Scheinin H, Lehtinen AM, Korttila KT.
Effect of intravenously administered dexmedetomidine on pain
after laparoscopic tubal ligation. Anesth Analg 1991;73:112–8.
[20] Tufanogullari B, White PF, Peixoto MP, et al. Dexmedeto-
midine infusion during laparoscopic bariatric surgery: the effect
on recovery outcome variables. Anesth Analg 2008;106:1741–8.
[21] Hindmarch I, Trick L, Ridout F. A double-blind, placebo- and
positive-internal-controlled (alprazolam) investigation of the
cognitive and psychomotor profile of pregabalin in healthy
volunteers. Psychopharmacology 2005;183:133–43.
[22] Agarwal A, Gautam S, Gupta D, Agarwal S, Singh PK, Singh
U. Evaluation of a single preoperative dose of pregabalin for
attenuation of postoperative pain after laparoscopic
cholecystectomy. Br J Anaesth 2008;101:700–4.
[23] Girija PR, Rahul Y, Arvind C, Hari HD. A63 effects of
pregabalin on postoperative pain and preoperative anxiety in
patients undergoing lumbar discectomy. Eur J Anaesth 2012;29
(Suppl. 49):S19.
[24] Zhang J, Ho KY, Wang Y. Efficacy of pregabalin in acute
postoperative pain: a meta-analysis. Br J Anaesth
2011;106:454–62.
